Legend Biotech Corporation
LEGNHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframePart of the healthcare sector, Legend Biotech Corporation (LEGN) is listed under Biotechnology. Valued at $4.31B, LEGN is a mid-cap name in its sector. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).
Market Cap
$4.31B
Beta
0.34
P/E (TTM)
—
P/E (Fwd)
20.28
EPS (TTM)
$-1.35
EPS (Fwd)
$1.10
ROE
-25.2%
ROA
-5.2%
Cash
$834.6M
Total Debt
$389.3M
Free CF
-$55.8M
52W Change
-46.5%
Annual Financials
Cash vs Debt
With $834.6M in cash and $389.3M in debt, LEGN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$55.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -25.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $68.8M (2021) to $1.03B (2025), reflecting a 1395% increase over the period.
The relatively low beta of 0.34 suggests LEGN is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, LEGN has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing LEGN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.